Evotec has scheduled an R&D Update in London at 13.00 pm BST (14.00 pm CET, 08.00 am US time East Coast) today which will be broadcast live on the internet. Evotec will also present details on this positive Phase II study in insomnia at that meeting.
For those who prefer to listen to the presentation via phone, please
dial:
From Europe: +49-(0)-69-5007-1308 (Germany)
+44-(0)-20-7806-1956 (UK)
From the US: +1-718-354-1388
Pass Code: 2793143
The on-demand version of the webcast will be available on our website:
http://www.evotec.com - Investors - Webcasts.
Notes to the Editor
Study design
This US, multi-centre, randomised, double-blind, placebo-controlled,
parallel group design trial was designed to evaluate the hypnotic efficacy
of EVT 201 in the treatment of primary insomnia in elderly patients with
daytime sleepiness. Patients were screened for entry into the study and the
eligibility criteria included: age greater than or equal to 65 years; a
diagnosis of primary insomnia according to DSM (Diagnostic and Statistical
Manual of Mental Disorders) IV; mean TST 240-410 minutes inclusive
determined during two consecutive nights polysomnography (PSG) evaluation;
mean MSLT greater than or equal to 4 and less than or equal to 16. Patients
were randomised to receive EVT 201 1.5 mg or EVT 201 2.5 mg or placebo for
seven consecutive nights. PSG data was collected for two nights at
Screening and on nights 1, 6 and 7 during the Treatment Period. The primary
endpoint of this trial was to assess Total Sleep Time (TST) determined by
PSG. The secondary endpoints included additional PSG-based measures such as
latency to persistent sleep, wake after sleep onset and effects on sleep
architecture. In addition, subjective sleep quality and quantity were
assessed, along with the Profile of Mood State (POMS). Daytime function was
assessed objectiv
'/>"/>
| SOURCE Evotec AG Copyright©2007 PR Newswire. All rights reserved |